Clinical Trial

Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).

Study acronym: PROMISE
Unknown Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 26, 2024 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of our study is to evaluate if the use of a precision-medicine approach with a specific therapy tailored on the underlying pathogenic mechanism will improve the quality-of-life in MINOCA patients. The investigators further aim at investigating wherever a precision-medicine approach will improve the prognosis, healthcare related costs, and if that a different profile of plasma biomarkers and microRNAs may serve as diagnostic tools for detecting specific causes of MINOCA and to assess response to therapy. Finally, beyond its pivotal role in differential diagnosis, the investigators hypothesize that cardiac magnetic resonance (CMR) may provide a morphological and functional cardiac characterization as well as help in the prognostic stratification.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05122780
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators: Centro Cardiologico Monzino, IRCCS Policlinico S. Donato
Conditions Myocardial Infarction With Non-Obstructive Coronary Arteries
Enrollment 120 participants
Start Date 2021-07-01
Primary Completion 2025-07 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2024-07-26